Agentix (AGTX) Liabilities and Shareholders Equity (2014 - 2026)
Agentix's (AGTX) quarterly Liabilities and Shareholders Equity came in at $771.0 in Q1 2026, down 99.23% YoY from $100274.0 in Q1 2025, and down 87.95% on a QoQ basis from $6396.0 in Q4 2025.
Agentix (AGTX) Liabilities and Shareholders Equity (2014 - 2026) Analysis & Trends
Agentix (AGTX) has 13 years of Liabilities and Shareholders Equity data on file, last reported at $771.0 in Q1 2026.
- Quarterly Liabilities and Shareholders Equity fell 99.23% year-over-year to $771.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $17180.0 (down 97.09% YoY) and the FY2026 annual result came in at $771.0, down 99.23% from the prior year.
- Liabilities and Shareholders Equity eased to $771.0 in Q1 2026, from $6396.0 in the prior quarter.
- In the past five years, Liabilities and Shareholders Equity ranged from a high of $333704.0 in Q3 2023 to a low of $771.0 in Q1 2026.
- A 5-year average of $114772.7 and a median of $106372.0 in 2024 frame the typical range for Liabilities and Shareholders Equity.
- Annual changes were most pronounced in 2023 — Liabilities and Shareholders Equity jumped 3809.83% — and 2026, when it sank 99.23%.
- Tracing AGTX's Liabilities and Shareholders Equity over 5 years: stood at $111475.0 in 2022, then grew by 0.43% to $111951.0 in 2023, then surged by 37.66% to $154111.0 in 2024, then slumped by 95.85% to $6396.0 in 2025, then slumped by 87.95% to $771.0 in 2026.
- The last three Liabilities and Shareholders Equity figures came in at $771.0 (Q1 2026), $6396.0 (Q4 2025), and $5601.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 27.42 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 41.73 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 10.03 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 10.96 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 9.18 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 5.56 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 25.60 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 2.10 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 19.82 Bn |
| 10 | Agentix | 801,339.00 | 801,301.00 | - | 38.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 38.00 |
| Mar 31, 2026 | 771.00 |
| Dec 31, 2025 | 6,396.00 |
| Sep 30, 2025 | 5,601.00 |
| Jun 30, 2025 | 4,412.00 |
| Mar 31, 2025 | 100,274.00 |
| Dec 31, 2024 | 154,111.00 |
| Sep 30, 2024 | 169,960.00 |
| Jun 30, 2024 | 166,946.00 |
| Mar 31, 2024 | 106,372.00 |
| Dec 31, 2023 | 111,951.00 |
| Sep 30, 2023 | 333,704.00 |
| Jun 30, 2023 | 330,500.00 |
| Mar 31, 2023 | 261,392.00 |
| Dec 31, 2022 | 111,475.00 |
| Sep 30, 2022 | 8,535.00 |
| Jun 30, 2022 | 11,022.00 |
| Feb 28, 2022 | 67,714.00 |
| Nov 30, 2021 | 50,676.00 |
| Aug 31, 2021 | 51,207.00 |